InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global Pen Needles Market– (By Type (Standard Pen Needles, Safety Pen Needles), By Length (4 mm, 5 mm, 6 mm, 8 mm, 10 mm, 12 mm), By Mode of Purchase (Retail, Non-retail), By Therapy (Insulin, Glucagon-Like Peptide-1, Growth Hormone, Other therapies)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031.”
According to the latest research by InsightAce Analytic, the Global Pen Needles Market is valued at USD 1.66 Bn in 2024, and it is expected to reach USD 3.43 Bn by the year 2031, with a CAGR of 10.95% during a forecast period of 2024-2031.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2733
Pen needles are precision-engineered devices designed for use with pen injectors, primarily for the subcutaneous administration of insulin by individuals managing diabetes through multiple daily injections. The global pen needle market is experiencing significant growth, driven by a confluence of key factors.
These include the rising global prevalence of diabetes, increasing preference for self-administered injectable therapies, and a broad range of pen needle options tailored to accommodate varying patient needs. Additionally, the growing emphasis on home-based healthcare and self-management practices is further contributing to market expansion.
The shift from traditional syringes to pen injectors—owing to their ease of use, improved patient compliance, and enhanced safety—has accelerated adoption rates. Technological advancements in pen needle design, particularly those aimed at improving safety and reducing injection discomfort, are further propelling market development.
Leading manufacturers are making substantial investments in product innovation, exemplified by next-generation devices such as the BD Nano™ 2nd Gen Pen Needles, which are specifically engineered to optimize comfort and precision during administration.
Furthermore, the widespread accessibility of pen needles through various distribution channels, including retail pharmacies, e-commerce platforms, and healthcare facilities, is strengthening market penetration and supporting sustained growth across diverse geographic regions.
List of Prominent Players in the Pen Needles Market:
- Becton, Dickinson, and Company (US),
- Novo Nordisk A/S (Denmark),
- Ypsomed Holding AG (Switzerland),
- B. Braun Melsungen AG (Germany),
- Owen Mumford (UK),
- Terumo Corporation (Japan),
- Nipro Corporation (Japan)
- Allison Medical (US),
- AdvaCare Pharma (US),
- Berpu Medical Technology (China),
- ARKRAY (Japan),
- GlucoRx (UK),
- HTL-STREFA (Poland),
- UltiMed, (US),
- Hindustan Syringes and Medical Devices (India),
- Artsana Group (Italy),
- PromiseMed Diabetes Care (Canada),
- Montmed (Canada),
- Trividia Health (US),
- VOGT Medical Vertrieb (Germany),
- Van Heek Medical (Netherlands),
- Simple Diagnostics (US),
- Lyon (Turkey),
- Links Medical Products (US),
- MHC Medical Products (US)
Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02
Market Dynamics
Drivers:
The rising incidence of chronic diseases—including diabetes, cardiovascular disorders, and multiple sclerosis—has significantly increased the demand for frequent and reliable drug delivery methods. Pen injectors have emerged as the preferred mode of administration for injectable therapies within the expanding healthcare landscape, primarily due to their user-friendly design, consistent performance, and ability to facilitate self-administration without requiring direct healthcare professional supervision.
Pen needles, the detachable components of these injectors, are essential for ensuring precise and effective drug delivery, with attributes such as length and sharpness playing a pivotal role in reaching the target tissue. As chronic disease rates continue to escalate globally, there is a growing demand for advanced pen needle technologies that support improved patient adherence and facilitate the efficient management of large patient populations.
Challenges:
Despite their advantages, pen needles present certain risks, including the potential for needlestick injuries, infections, patient discomfort, and dosage inaccuracies that may lead to complications such as hyperglycemia. For example, some patients using insulin pens encounter difficulties in dosage control, prompting a shift in diabetes management strategies.
In regions such as Europe, insulin pumps—offering features such as automated insulin suspension and reduced hypoglycemia risk—are increasingly favored over traditional pen-based therapy. This shift poses a competitive challenge to the pen needle market. Additionally, although needle-free drug delivery systems address some of the limitations associated with needle use, their practical applications remain restricted at present.
Regional Trends:
The Asia-Pacific (APAC) region is poised for significant growth in the pen needle market during the forecast period. This expansion is driven by a growing preference for pen needles over conventional syringes and vials, alongside a rapidly aging population. China, in particular, is emerging as a key contributor to regional market growth, fueled by the increasing prevalence of diabetes.
According to the “Guidelines for the Prevention and Treatment of Diabetes in China (2020 Edition),” the national diabetes prevalence among adults is 11.2%, affecting approximately 141 million individuals—more than half of whom remain undiagnosed. These figures underscore the urgent need for accessible, effective drug delivery solutions and are expected to support sustained market growth in the region.
Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2733
Recent Developments:
- In February 2023, Montmed, Inc. announced, the United States Patent and Trademark Office has issued a second US Patent 11,517,659, expanding the company’s novel technology patent family that aims to help insulin users develop and implement healthy injection site rotation practices easily and seamlessly.
- In May 2022, Owen Mumford Ltd. revealed its next-generation safety pen needle will join Unifine SafeControl to enhance its diabetic care products. The first safety pen needle, Unifine SafeControl, protects healthcare professionals from needlestick accidents and ensures the full medication dose is given.
- In Jan 2019, Becton Dickinson (BD) introduced the Ergonomic Pen Needle Technology with the aim of enhancing the efficiency of injection techniques. The BD Nano(TM) second generation pen needle has obtained 510(k) clearance from the U.S. Food and Drug Administration.
Segmentation of Pen Needles Market-
By Type-
- Standard Pen Needles
- Safety Pen Needles
By Length-
- 4 mm Pen Needle
- 5 mm Pen Needle
- 6 mm Pen Needle
- 8 mm Pen Needle
- 10 mm Pen Needle
- 12 mm Pen Needle
By Mode of Purchase-
- Retail
- Non-retail
By Therapy-
- Insulin
- Glucagon-Like Peptide-1
- Growth Hormone
- Other therapies
By Region-
North America-
- The US
- Canada
- Mexico
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com
